Genentech

Genentech is the fifth highest growth companies in the world. Its 1 year Revenues is $9,284(millions). D. Levinson, Ph.D.Chairman and Chief Executive Officer of Genentech.
What makes it so great?Legendarily perk-heavy biotech firm bumped up 401(k)match in 2007(100% up to 5% of pay).
Genentech was founded 30 years ago, in 1976, by the late venture capitalist Robert A. Swanson and the biochemist Dr. Herbert W. Boyer. In the early 1970s, Boyer and geneticist Stanley Cohen pioneered a new scientific field called recombinant DNA technology. Upon learning about this development, Swanson placed a call to Boyer and requested a meeting. Boyer agreed to give the young entrepreneur 10 minutes of his time. Swanson's enthusiasm for the technology and his faith in its commercial potential were contagious, and the meeting extended from 10 minutes to three hours; by its conclusion, Genentech was born. Though Swanson and Boyer faced skepticism from both the academic and business communities, they forged ahead with their idea.
The company's goal was to develop a new generation of therapeutics created from genetically engineered copies of naturally occurring molecules important in human health and disease. Within a few short years, Genentech scientists proved it was possible to make medicines by splicing genes into fast-growing bacteria that produced therapeutic proteins. Today Genentech continues to use genetic engineering techniques and advanced technologies to develop medicines that address significant unmet needs and provide clinical benefits to millions of patients worldwide.
• FORTUNE named Genentech one of the "100 Best Companies to Work For" for the tenth consecutive year. This year Genentech was number five on the list.
• Genentech received FDA approval for Herceptin as a singe agent, for the adjuvant treatment of HER2-overexpressing node-negative (ER/PR-negative or with one high risk feature) or node-positive breast cancer, following multi-modality anthracycline-based therapy.
• Genentech received FDA approval for its supplemental Biologics License Application (sBLA) to expand the label for Rituxan to treat adult patients with moderate-to-severe rheumatoid arthritis (RA) in combination with methotrexate (MTX) to slow the progression of structural damage.
DOWNLOAD UNLIMITED GAMES AND MOVIES ON YOUR PC